Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW) Short Interest Update
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW – Get Rating) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 24,800 shares, a growth of 37.
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW) Short Interest Up 37.8% in January
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW – Get Rating) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 24,800 shares,
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA) Sees Large Growth in Short Interest
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA – Get Rating) was the recipient of a significant growth in short interest during the month of January. As of January 31st, there was short interest t
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures Regarding Excise Tax
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement With SEC in Connection With Its Proposed Business Combination With Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ:AEHA) ("Aesther"), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. ("Ocean"), a
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW) Sees Large Decline in Short Interest
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW – Get Rating) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 20,200 shares
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW) Sees Large Increase in Short Interest
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHAW – Get Rating) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 23,500 sha
Novel Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis, Unveiling the Potential for a New Class of Antimalarial Drugs.
• Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, "OCEA
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA) Short Interest Update
Aesther Healthcare Acquisition Corp. (NASDAQ:AEHA – Get Rating) saw a significant increase in short interest in October. As of October 15th, there was short interest totalling 1,600 shares, an incre
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce Execution of a Second up to $40 Million Backstop Agreement, for a Total of up to $80 Million
NEW YORK and PROVIDENCE, R.I., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) ("Aesther"), a special purpose acquisition company ("SPAC") and Ocean Biomedical,
Building on Their Innovative MRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., an
Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination
New York, NY and Providence, RI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. ("Aesther") (NASDAQ: AEHA) entered into definiti
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Preliminary Proxy Statement With SEC in Connection With Its Proposed Business Combination With Ocean Biomedical, Inc.
NEW YORK and PROVIDENCE, R.I., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) ("Aesther"), a special purpose acquisition company (SPAC) and Ocean Biomedical, I
Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination
New York, NY and Providence, RI, Sept. 12, 2022 (GLOBE NEWSWIRE) -- As previously announced, on August 30, 2022, Aesther Healthcare Acquisition Corp. ("Aesther") (NASDAQ: AEHA) entered into definiti
SPAC Aesther Healthcare Closes up to $75M Share Purchase Agreement With White Lion Capital
Special purpose acquisition company Aesther Healthcare Acquisition (NASDAQ:AEHA), planning to merge with the cancer drug company Ocean Biomedical (OCEA), closed an up to $75M share purchase agreement
Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) and Ocean Biomedical, Inc. Announce $75 Million Common Stock Purchase Transaction With White Lion Capital
Globe Newswire 8-Sep-2022 8:07 AMNEWS PROVIDED BY Aesther Healthcare Acquisition Corp (NASDAQ:AEHA) September 8, 2022, 07:45 am ET NEW YORK and PROVIDENCE, R.I., Sept. 08, 2022 (GLOBE NEWSWIRE) --
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors Which Kill Glioblastoma and Block the Metastasis of Malignant Melanoma Cells to the Lung By Over 90% Announced by Ocean Biomedical and Aesther Healthcare (NASDAQ: AEHA)
Fig. 1 Tumor cell death was not induced by isotype control antibodies, and modest degrees of tumor cell apoptosis were seen in cultures with monospecific antiCHI3L1, antiPD-1 or antiCTLA4 individuall
Aesther Healthcare Acquisition Corp. Has Entered Into an Agreement and Plan of Merger With Ocean Biomedical, Inc., a Next-Generation Biopharma Company, to List on NASDAQ
Ocean Biomedical's innovative business model bridges the 'bench-to-bedside' gap by accelerating the commercialization of innovative assets from research universities and medical centers.Ocean Biomedic
Record M & An activity gives Wall Street the best performance in the history of the investment banking division of Morgan Stanley.
Thanks to the red-hot pace of mergers and acquisitions, Morgan Stanley investment bankers posted their best quarterly performance in history. According to Morgan Stanley's statement, the division's third-quarter revenue rose 67% to $2.85 billion, exceeding analysts' expectations and helping to boost the company's overall profitability. Revenue from stock trading rose 24% to $2.9 billion. Dongfeng, which has boosted by mergers and acquisitions and trading activity, has made a lot of money since the outbreak. Now, as deal activity slows and investment bankers take over, booming capital markets and M & An advice have brought them record commissions. Bank of America Corporation
Nothing can stop the Federal Reserve from cutting back in November, even non-farm payroll data won't work
Inflation and labor market performance may have met the prerequisites for a reduction in debt purchases. Federal Reserve hawks will emphasize that wages are growing quite fast, which is a sign that the labor market continues to tighten. Federal Reserve policymakers may not pay too much attention to September's weak non-farm payroll data; they expect to take the first step in withdrawing from stimulus policies at next month's monetary policy meeting. Rubeela Farooqi, chief US economist at High Frequency Economics, said, “This will not change the Fed's reduction schedule. Inflation and labor market performance may have satisfied the reduction in debt purchases before
No Data